<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04272606</url>
  </required_header>
  <id_info>
    <org_study_id>201912099</org_study_id>
    <nct_id>NCT04272606</nct_id>
  </id_info>
  <brief_title>TXA in Spinal Fusion</brief_title>
  <official_title>Randomized Clinical Trial for Tranexamic Acid (TXA) in Lumbar Interbody Spinal Fusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mario Zanaty</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tranexamic acid and placebo will be given during surgery to patients who have elected to&#xD;
      undergo lumber interbody fusion on 2 or more levels. Information regarding blood loss,&#xD;
      transfusions needed, and duration of hospital stay will be collected.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to assess whether tranexamic acid (a drug that is used to coagulate the blood&#xD;
      and reduce bleeding) use in lumbar spinal fusion can reduce blood loss compared to placebo.&#xD;
      Thusly reducing need for transfusion, shorting the hospital stay and improving outcomes. For&#xD;
      this the study will randomize patients who are receiving elective lumbar interbody fusion&#xD;
      (PLIF or TLIF) of 2 or more levels for degenerative disc disease (DDD) into 2 groups. Group 1&#xD;
      would receive tranexamic acid during the surgery while group 2 will receive placebo. Blood&#xD;
      loss during the surgery and postoperatively (while the patient has a drain) will be monitored&#xD;
      along with the amount of transfusions needed and the duration of hospital stay.&#xD;
&#xD;
      The drug or placebo are only given during the surgery. The patient population includes&#xD;
      elective cases of patient undergoing lumbar spinal fusion of 2 or more levels. Spinal fusions&#xD;
      are known to be associated with blood loss, especially when the surgeries are long and more&#xD;
      levels need to be fused.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 2B randomized, single-center, double-blinded, placebo vs treatment clinical trial with 1:1 randomization</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transfusion</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Amount (in cells cubed) of red blood cells (RBC) transfused intraoperatively and up to 7 days post-operatively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Loss</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Amount (in cells cubed) of blood loss intraoperatively and up to 7 days post-operatively</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Degenerative Disc Disease</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1:1 randomization, given tranexamic acid during surgery, visual acuity exam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1:1 randomization, given standard of care treatment during surgery, visual acuity exam</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Antifibrinolytic Agent</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Solution</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Visual Acuity Exam</intervention_name>
    <description>Supplemented into standard of care daily neurological exam on day of surgery and day after</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Eye Exam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-80 years&#xD;
&#xD;
          2. American Spinal Injury Association (ASIA) Impairment Scale anesthesia risk of I to IV&#xD;
&#xD;
          3. Body Mass Index (BMI) of&lt;35&#xD;
&#xD;
          4. Patients undergoing 2 or more levels of posterior lumbar interbody fusion for DDD.&#xD;
             This includes PLIF or TLIF.&#xD;
&#xD;
          5. Patients have failed conservative management, which include physical therapy (PT) or&#xD;
             occupational therapy (OT) and/or injections.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. ASIA class V&#xD;
&#xD;
          2. Patient unable to consent&#xD;
&#xD;
          3. Patient with chronic kidney disease stage III or above: baseline plasma&#xD;
             creatinine&gt;1.5mg/dL&#xD;
&#xD;
          4. Patient with known liver failure&#xD;
&#xD;
          5. Patients on anticoagulation or dual antiplatelets (presence of vascular stents).&#xD;
&#xD;
          6. Patients with artificial valves.&#xD;
&#xD;
          7. Patients with allergy to TXA&#xD;
&#xD;
          8. Patients with platelet count &lt; 150 000,&#xD;
&#xD;
          9. Patients with PT&lt;60%&#xD;
&#xD;
         10. Patients with Activated Partial Thromboplastin Time (APPT) &gt;38s&#xD;
&#xD;
         11. History of stroke or (an) unprovoked thromboembolic event(s).&#xD;
&#xD;
         12. History of intracranial bleeding,&#xD;
&#xD;
         13. Pregnancy&#xD;
&#xD;
         14. known defective color vision&#xD;
&#xD;
         15. history of venous or arterial thromboembolism or active thromboembolic disease&#xD;
&#xD;
         16. Patients with severe pulmonary or cardiac disease.&#xD;
&#xD;
         17. Patients who refuse transfusion of blood products&#xD;
&#xD;
         18. Patients with chronic anemia with Hg&lt;8&#xD;
&#xD;
         19. Patients undergoing lumbar fusion for disease other than DDD (neoplasm)&#xD;
&#xD;
         20. Patients undergoing lumbar fusion by anterior or lateral approach.&#xD;
&#xD;
         21. Minimally invasive TLIF are excluded.&#xD;
&#xD;
         22. Emergent cases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Zanaty, M.D&gt;</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eleanor C Ryan</last_name>
    <phone>319-467-5677</phone>
    <email>eleanor-ryan@uiowa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mario Zanaty, M.D.</last_name>
    <phone>(319) 356-7643</phone>
    <email>mario-zanaty@uiowa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleanor C Ryan</last_name>
      <phone>937-570-2541</phone>
      <email>eleanor-ryan@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mario Zanaty, M.D.</last_name>
      <phone>(319) 356-7643</phone>
      <email>mario-zanaty@uiowa.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 13, 2020</study_first_submitted>
  <study_first_submitted_qc>February 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>August 14, 2020</last_update_submitted>
  <last_update_submitted_qc>August 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Mario Zanaty</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Posterior Lumbar Interbody Fusion</keyword>
  <keyword>Transforaminal Lumbar Interbody Fusion</keyword>
  <keyword>Tranexamic Acid</keyword>
  <keyword>Neurosurgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

